0
Abstract: Poster Presentations |

PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH WARFARIN HAVE A HIGHER PREVALENCE OF MITRAL VALVE CALCIUM, MITRAL ANNULAR CALCIUM, OR AORTIC VALVE CALCIUM THAN PATIENTS NOT TREATED WITH WARFARIN FREE TO VIEW

Chandrasekar Palaniswamy, MD*; Wilbert S. Aronow, MD; Chul Ahn, PhD; Tarunjit Singh, MD; Arunabh Sekhri, MD; Robert G. Lerner, MD
Author and Funding Information

New York Medical College, Valhalla, NY


Chest


Chest. 2009;136(4_MeetingAbstracts):99S-b-100S. doi:10.1378/chest.136.4_MeetingAbstracts.99S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  To investigate the prevalence of mital valve calcium (MVC), mitral annular calcium (MAC), and aortic valve calcium (AVC) in patients with non-valvular atrial fibrillation (AF) treated with warfarin versus no warfarin.

METHODS:  Of 1155 patients, mean age 74 years, with AF, 725 (63%) were treated with warfarin and 430 (37%) without warfarin. The prevalence of MVC, MAC, and AVC was investigated in these 1155 patients by 2-dimensional echocardiograms.

RESULTS:  MVC was present in 89 of 725 patients (12%) on warfarin versus 36 of 430 patients (8%) not on warfarin (p = 0.039). MAC was present in 275 of 725 patients (38%) on warfarin versus 140 of 430 patients (33%) not on warfarin (p = 0.066). AVC was present in 351 of 725 patients (48%) on warfarin versus 166 of 430 patients (39%) not on warfarin (p = 0.001). MVC, MAC, or AVC was present in 473 of 725 patients (65%) on warfarin versus 225 of 430 patients (52%) not on warfarin (p < 0.0001). Using the variables age, gender, race, ejection fraction, smoking, hypertension, diabetes, dyslipidemia, coronary artery disease (CAD), glomerular filtration rate, calcium, phosphorus, calcium-phosphorus product, alkaline phosphatase, use of aspirin, beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins, stepwise logistic regression analysis showed that significant risk factors associated with MVC, MAC, or AVC were CAD (odds ratio = 13.6, p < 0.0001), use of warfarin (odds ratio = 2.3, p < 0.0001), age (1.08 per 1 year increase, p < 0.0001), calcium-phosphorus product (odds ratio = 1.02, p = 0.015), and dyslipidemia (odds ratio = 0.13, p < 0.0001).

CONCLUSION:  Use of warfarin in patients with AF is associated with an increased prevalence of MVC, MAC, or AVC.

CLINICAL IMPLICATIONS:  Use of warfarin in patients with AF is associated with an increased prevalence of MVC, MAC, or AVC. Alternative drugs are needed to treat AF.

DISCLOSURE:  Chandrasekar Palaniswamy, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
Venous thromboembolism (VTE).
University of Michigan Health System | 7/31/2009
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543